LncRNA XIST/miR-34a 轴通过 MET-PI3K-AKT 信号通路调节甲状腺癌细胞增殖和肿瘤生长。

LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.

机构信息

Nuclear Medicine Department, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.

Oncology Department, Xiangya Hospital, Central South University, Changsha, No. 87 Xiangya Road, Changsha, Hunan, 410008, People's Republic of China.

出版信息

J Exp Clin Cancer Res. 2018 Nov 21;37(1):279. doi: 10.1186/s13046-018-0950-9.

DOI:10.1186/s13046-018-0950-9

PMID:30463570

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6249781/

Abstract

BACKGROUND

Thyroid cancer is one of the most prevalent malignancies in endocrine system. Further understanding and revealing the molecular mechanism underlying thyroid cancer are indispensable for the development of effective diagnosis and treatments. In the present study, we attempted to provide novel basis for targeted therapy for thyroid cancer from the aspect of lncRNA-miRNA-mRNA interaction.

METHODS

The expression and cellular function of XIST (X-inactive specific transcript) was determined. miRNAs which may be direct targets of XIST were screened for from online GEO database and miR-34a was selected. Next, the predicted binding between XIST and miR-34a, and the dynamic effect of XIST and miR-34a on downstream MET (hepatocyte growth factor receptor)-PI3K (phosphoinositide 3-kinase)-AKT (α-serine/threonine-protein kinase) signaling was evaluated.

RESULTS

XIST was significantly up-regulated in thyroid cancer tissues and cell lines; XIST knockdown suppressed the cell proliferation in vivo and the tumor growth in vitro. Based on online database and online tool prediction results, miR-34a was underexpressed in thyroid cancer and might be a direct target of XIST. Herein, we confirmed the negative interaction between XIST and miR-34a; moreover, XIST knockdown could reduce the protein levels of MET, a downstream target of miR-34a, and the phosphorylation of PI3K and AKT. In thyroid cancer tissues, MET mRNA and protein levels of MET were up-regulated; MET was positively correlated with XIST while negatively correlated with miR-34a, further confirming that XIST serves as a ceRNA for miR-34a through sponging miR-34a, competing with MET for miR-34a binding, and finally modulating thyroid cancer cell proliferation and tumor growth.

CONCLUSION

In the present study, we provided novel experimental basis for targeted therapy for thyroid cancer from the aspect of lncRNA-miRNA-mRNA interaction.

摘要

背景

甲状腺癌是内分泌系统最常见的恶性肿瘤之一。进一步了解和揭示甲状腺癌的分子机制对于开发有效的诊断和治疗方法是必不可少的。在本研究中，我们试图从 lncRNA-miRNA-mRNA 相互作用的角度为甲状腺癌的靶向治疗提供新的依据。

方法

测定 XIST（X 染色体失活特异性转录本）的表达和细胞功能。从在线 GEO 数据库筛选可能是 XIST 的直接靶标的 miRNAs，并选择 miR-34a。接下来，评估 XIST 和 miR-34a 之间的预测结合以及 XIST 和 miR-34a 对下游 MET（肝细胞生长因子受体）-PI3K（磷酸肌醇 3-激酶）-AKT（α-丝氨酸/苏氨酸蛋白激酶）信号的动态影响。

结果

XIST 在甲状腺癌组织和细胞系中显著上调；XIST 敲低抑制体内细胞增殖和体外肿瘤生长。基于在线数据库和在线工具预测结果，miR-34a 在甲状腺癌中表达下调，可能是 XIST 的直接靶标。在此，我们证实了 XIST 和 miR-34a 之间的负相互作用；此外，XIST 敲低可降低 MET 的蛋白水平，MET 是 miR-34a 的下游靶标，PI3K 和 AKT 的磷酸化。在甲状腺癌组织中，MET mRNA 和蛋白水平上调；MET 与 XIST 呈正相关，与 miR-34a 呈负相关，进一步证实 XIST 通过海绵 miR-34a 作为 miR-34a 的 ceRNA，与 MET 竞争 miR-34a 结合，最终调节甲状腺癌细胞增殖和肿瘤生长。

结论

在本研究中，我们从 lncRNA-miRNA-mRNA 相互作用的角度为甲状腺癌的靶向治疗提供了新的实验依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fd2/6249781/872a76e8d8c4/13046_2018_950_Fig1_HTML.jpg

相似文献

LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.

J Exp Clin Cancer Res. 2018 Nov 21;37(1):279. doi: 10.1186/s13046-018-0950-9.

MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.

Biochem Biophys Res Commun. 2013 Nov 29;441(4):958-63. doi: 10.1016/j.bbrc.2013.11.010. Epub 2013 Nov 9.

Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.

Int J Biol Macromol. 2018 Feb;107(Pt B):2620-2629. doi: 10.1016/j.ijbiomac.2017.10.154. Epub 2017 Oct 26.

Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway.

Cell Cycle. 2019 Jan;18(2):167-203. doi: 10.1080/15384101.2018.1560203. Epub 2018 Dec 30.

Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression.

J Hematol Oncol. 2018 Jul 3;11(1):89. doi: 10.1186/s13045-018-0632-2.

LncRNA-XIST/microRNA-126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma.

J Cell Biochem. 2020 Mar;121(3):2170-2183. doi: 10.1002/jcb.29440. Epub 2019 Nov 3.

MiR-1246 regulates the PI3K/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth.

Mol Cell Biochem. 2022 Mar;477(3):649-661. doi: 10.1007/s11010-021-04290-3. Epub 2021 Dec 6.

lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.

Pathol Res Pract. 2019 Mar;215(3):555-563. doi: 10.1016/j.prp.2018.12.013. Epub 2018 Dec 12.

LncRNA XIST Promotes Migration and Invasion of Papillary Thyroid Cancer Cell by Modulating MiR-101-3p/CLDN1 Axis.

Biochem Genet. 2021 Apr;59(2):437-452. doi: 10.1007/s10528-020-09985-8. Epub 2020 Oct 14.

STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.

Cell Prolif. 2019 Mar;52(2):e12569. doi: 10.1111/cpr.12569. Epub 2019 Jan 18.

引用本文的文献

Involvement of lncRNA in cancer diagnosis and prognosis and clinical implications.

Rep Pract Oncol Radiother. 2025 Aug 7;30(3):439-450. doi: 10.5603/rpor.106487. eCollection 2025.

Molecular interaction of human papilloma virus (HPV) with microRANs: insights into the development of cervical cancer and treatment approaches.

Infect Agent Cancer. 2025 Jul 23;20(1):49. doi: 10.1186/s13027-025-00677-9.

DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway.

Sci Rep. 2025 Jul 1;15(1):21780. doi: 10.1038/s41598-025-06748-6.

Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.

Mol Cancer. 2025 Mar 11;24(1):74. doi: 10.1186/s12943-025-02263-4.

Pan-cancer analysis of Methyltransferase-like 16 (METTL16) and validated in colorectal cancer.

Aging (Albany NY). 2025 Feb 27;17(2):588-606. doi: 10.18632/aging.206210.

Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.

Noncoding RNA Res. 2024 Dec 3;11:1-21. doi: 10.1016/j.ncrna.2024.11.006. eCollection 2025 Apr.

Nanoparticles (NPs)-meditated si-lncRNA NONHSAT159592.1 inhibits glioblastoma progression and invasion through targeting the ITGA3/FAK/PI3K/AKT pathway.

Metab Brain Dis. 2024 Nov 21;40(1):31. doi: 10.1007/s11011-024-01471-z.

LINC00261 triggers DNA damage via the miR-23a-3p/CELF2 axis to mitigate the malignant characteristics of I-resistant papillary thyroid carcinoma cells.

Biochem Biophys Rep. 2024 Oct 30;40:101858. doi: 10.1016/j.bbrep.2024.101858. eCollection 2024 Dec.

Colon Cancer-Derived Exosomal LncRNA-XIST Promotes M2-like Macrophage Polarization by Regulating PDGFRA.

Int J Mol Sci. 2024 Oct 24;25(21):11433. doi: 10.3390/ijms252111433.

Tight Junctions and Cancer: Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies.

Pharmaceuticals (Basel). 2024 Sep 30;17(10):1304. doi: 10.3390/ph17101304.

本文引用的文献

Long non-coding RNA XIST promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer.

Cancer Lett. 2018 Apr 1;418:185-195. doi: 10.1016/j.canlet.2018.01.036. Epub 2018 Jan 17.

LncRNA MALAT1 acts as an oncogene in multiple myeloma through sponging miR-509-5p to modulate FOXP1 expression.

Oncotarget. 2017 Oct 23;8(60):101984-101993. doi: 10.18632/oncotarget.21957. eCollection 2017 Nov 24.

Long non-coding RNA XIST promotes cell growth and metastasis through regulating miR-139-5p mediated Wnt/β-catenin signaling pathway in bladder cancer.

Oncotarget. 2017 Oct 10;8(55):94554-94568. doi: 10.18632/oncotarget.21791. eCollection 2017 Nov 7.

Prospective lncRNA-miRNA-mRNA regulatory network of long non-coding RNA LINC00968 in non-small cell lung cancer A549 cells: A miRNA microarray and bioinformatics investigation.

Int J Mol Med. 2017 Dec;40(6):1895-1906. doi: 10.3892/ijmm.2017.3187. Epub 2017 Oct 12.

Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer.

Biomed Pharmacother. 2017 Nov;95:922-928. doi: 10.1016/j.biopha.2017.09.005. Epub 2017 Sep 12.

WITHDRAWN: LncRNA-HOTAIR Activates Tumor Cell Proliferation and Migration by Suppressing MiR-326 in Cervical Cancer.

Oncol Res. 2017 Aug 31. doi: 10.3727/096504017X15037515496840.

The Long Non-Coding RNA XIST Interacted with MiR-124 to Modulate Bladder Cancer Growth, Invasion and Migration by Targeting Androgen Receptor (AR).

Cell Physiol Biochem. 2017;43(1):405-418. doi: 10.1159/000480419. Epub 2017 Aug 31.

Key signaling pathways in thyroid cancer.

J Endocrinol. 2017 Nov;235(2):R43-R61. doi: 10.1530/JOE-17-0266.

Analyzing the LncRNA, miRNA, and mRNA Regulatory Network in Prostate Cancer with Bioinformatics Software.

J Comput Biol. 2018 Feb;25(2):146-157. doi: 10.1089/cmb.2016.0093. Epub 2017 Aug 24.

LncRNA-XIST interacts with to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway.

Biosci Rep. 2017 Sep 7;37(5). doi: 10.1042/BSR20170696. Print 2017 Oct 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

LncRNA XIST/miR-34a 轴通过 MET-PI3K-AKT 信号通路调节甲状腺癌细胞增殖和肿瘤生长。

LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.

机构信息

Nuclear Medicine Department, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.

Oncology Department, Xiangya Hospital, Central South University, Changsha, No. 87 Xiangya Road, Changsha, Hunan, 410008, People's Republic of China.